Join as an individual or organization
КІРІСПЕ: 2010-шы жылдардың ортасындағы қолайлы саяси ахуалда есiрткiнiң алдын алу саласындағы жобаларды жоспарлауды қолдау үшiн EDPQS (ASPIRE) шолуынан берiлген алдын алу бағдарламаларын бағалау және iрiктеу стандарттары әзiрлендi.
ӘДІСТ...
INTRODUCTION: The Cyprus National Addictions Authority (NAAC) is the main coordinating body for all matters related to licit and illicit substances as well as pathological gambling in Cyprus and it is responsible, inter alia, for the...
BACKGROUND: The implementation of quality standards in the treatment of substance use disorders in Lithuania is not well documented in the literature. AIMS: To describe the process of the development of quality standards from grassroots...
Sexual and gender minority individuals face marked disparities in substance use.
This narrative review explores research on substance use in sexual and gender minority communities. The authors define the sexual and gender minority...
Professor Carol Emslie and David Barbour discuss research on gender, identity and drinking, and the disproportionate impact of substance use in the LGBT+ community.
In this research, the authors explored how lesbian, gay, bisexual, transgender, and queer (LGBTQ) young adults with problematic substance use made sense of their substance use in relation to their LGBTQ identities.
The authors...
This briefing provides a summary of alcohol consumption, alcohol harm, alcohol treatment, and gaps in knowledge regarding alcohol use among LGBTQ+ people.
It uses the acronym LGBTQ+ to include lesbian, gay, bisexual, transgender, queer...
Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ+) Pride month is celebrated each year during the month of June. Here you can find a list of resources and research on the topic of substance use among the LGBTQ+ community.
1) This rep...
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national...
Despite extensive evidence regarding the negative effects of stigma experienced by people living with HIV (PLHIV) and people who inject drugs within health care settings, comparatively little evidence exists regarding the effectiveness of...
Alcohol and other drug treatment are generally only provided for individuals, often away from their families. Treatment aims to improve well-being and reduce the harms of substance use and families and communities can play a significant...
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
Substance use disorders (SUDs) are highly prevalent and impact individuals' health, well-being, and social functioning. Long-lasting changes in brain networks involved in reward, executive function, stress reactivity, mood, and...
Presented by Richard Rawson, PhD, Emeritus Professor in the Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine and a Research Professor at the University of Vermont, this presentation provided an overview of the...
In the magazine CIJ Informa, the participation of CIJ, host chapter institution of ISSUP Mexico, in the 71st Regular Session of CICAD is reviewed.
The Anti-Stigma Network has been launched!
The Anti-Stigma Network has been created by a group of organisations coming together with a shared mission.
Collectively they aim to improve understanding of the stigma and...
Background
Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for people who receive this treatment. Methadone and...
The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine...